|
|
Volumn 367, Issue 19, 2012, Pages 1847-1848
|
|
The promise of antibody-drug conjugates
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY;
BRENTUXIMAB VEDOTIN;
CAPECITABINE;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
IMMUNOGLOBULIN;
LAPATINIB;
TRASTUZUMAB EMTANSINE;
ADVANCED CANCER;
BREAST CANCER;
CANCER COMBINATION CHEMOTHERAPY;
CANCER PATIENT;
CANCER RESISTANCE;
CANCER SURVIVAL;
CELL MEDIATED CYTOTOXICITY;
CLINICAL EFFECTIVENESS;
DRUG CONJUGATION;
DRUG EFFICACY;
DRUG SAFETY;
EDITORIAL;
HODGKIN DISEASE;
HUMAN;
IMMUNOGENICITY;
LARGE CELL LYMPHOMA;
NONHUMAN;
OUTCOME ASSESSMENT;
OVERALL SURVIVAL;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
PROTEIN EXPRESSION;
PROTEIN TARGETING;
VISCERAL METASTASIS;
|
|
EID: 84868595258
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMe1211736 Document Type: Editorial |
|
Times cited : (45)
|
|
References (7)
|
